Research4h ago0 views

Antimicrobial-potentiated colorectal cancer therapy with synchronized tumoricidal immunity via a self-deliverable nanopeptide.

Peptide-based nanodrugs just showed up big in colorectal cancer research. A Chinese team engineered a self-deliverable nanopeptide that does two things at once: it hits colorectal cancer cells and wipes out Fusobacterium nucleatum, a key bacterial driver of tumor progression and resistance.

Acta Biomater

by Wei SN, Cai C, Wang J et al.

“Antimicrobial-potentiated colorectal cancer therapy with synchronized tumoricidal immunity via a self-deliverable nanopeptide. Wei SN(1), Cai C(1), Wang J(2), Zhang DY(1), Min J(2), Zhang Y(3), Wang LJ(3), Liu WL(1), Cheng YJ(1), Han XL(4), Li X(5), Qin SY(6). Author information: (1)Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Key Laboratory of Catalysis and Materials Science, South-Central Minzu University, Wuhan 430074, P. R. China. (2)Department of Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, P. R. China. (3)Hubei Key Laboratory of Purification and Application of Plant Anti-cancer Active Ingredients, Hubei University of Education, Wuhan 430205, P. R. China. (4)Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Key Laboratory of Catalysis and Materials Science, South-Central Minzu University, Wuhan 430074, P. R. China. Electronic address: HXL1220@hotmail.com. (5)Department of Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, P. R. China. Electronic address: xin.li@whu.edu.cn. (6)Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Key Laboratory of Catalysis and Materials Science, South-Central Minzu University, Wuhan 430074, P. R. China. Electronic address: sy-qin@mail.scuec.edu.cn. As one of the core pathogens of colorectal cancer (CRC), fusobacterium nucleatum (Fn) contributes to tumor progression, drug-resistance, and immunosuppressive microenvironment, resulting in low therapeutic outcomes. Developing multifunctional nanodrugs capable of tandem killing cancer cells and intratumoral Fn while circumventing drug-resistance and remodeling immunosuppressive niche is very promising but faces enormous challenges. Herein, a self-deliverable nanodrug composed of single-component peptide was developed to combat Fn-colonized CRC. Relying on peptide self-assembly, the nanodrug was readily fabricated without carriers, which dually killed CRC cells and Fn via membrane disruption mechanism and thus mitigated the drug-resistance. To selectively eliminate cancer cells and pathogens, an acidity-activated charge conversion strategy was exploited to decorate peptide drug. Concurrently, this approach mitigated hemolytic side effects and enhanced pharmacological stability. Notably, peptide-mediated immunogenic cell death (ICD) and killed Fn further separately released damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) to synergistically activate the host immune response for immunotherapy. Furthermore, the multifunctional nanopeptide could block epithelial-mesenchymal transition (EMT) process, showing the potential of inhibiting Fn-colonized CRC metastasis. Collectively, this single-component peptide nanodrug demonstrates a well-defined composition, facile synthesis, tumor-specific activation, and superior therapeutic efficacy in CRC treatment, presenting a strong case for its future clinical application. STATEMENT OF SIGNIFICANCE: Intratumoral Fusobacterium nucleatum (Fn) drives colorectal cancer (CRC) progression, chemoresistance, and immunosuppression, creating a critical barrier to effective therapy. To address this, we developed a single-component, self-deliverable nanopeptide with an acidity-activated charge-conversion mechanism. This nanodrug achieved tandem membrane-disruption-mediated killing of both CRC cells and intratumoral Fn, a physical mechanism that circumvents conventional drug resistance. Its acidity-activated charge conversion further ensured tumor-selective activation while minimizing hemolytic toxicity. Beyond its dual cytotoxic action, it also activated host antitumor immunity and blocked epithelial-mesenchymal transition (EMT) in Fn-infected CRC. With its well-defined composition, facile synthesis, and tumor-specific activation, this peptide-based nanoplatform offers a transformative strategy for overcoming pathogen-driven therapeutic resistance and advancing CRC treatment toward clinical translation. Copyright © 2026. Published by Elsevier Inc. Conflict of interest statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.”

Here’s what makes this stand out. The nanopeptide forms itself—no carrier system needed. Once inside the acidic tumor environment, it flips its charge. That means it activates right where it’s needed, sparing healthy cells and minimizing unwanted side effects like hemolysis. The mechanism? Membrane disruption. Both the cancer cells and the bacteria get taken out physically, not chemically. This sidesteps the classic drug resistance that plagues standard therapies.

But the real kicker is what happens next. Killing off the cancer cells and bacteria unleashes a storm of cell and pathogen signals—DAMPs and PAMPs. These signals light up the immune system, pushing the body’s own defenses to join the fight. There’s also evidence that this peptide blocks the epithelial-mesenchymal transition, which is research-speak for “shutting down the cancer’s ability to spread.”

Key takeaway:

•

Single-component, self-assembling peptide nanodrug

•

Dual action: destroys cancer cells and intratumoral bacteria

•

Tumor-specific, acidity-activated mechanism minimizes off-target effects

•

Boosts immune response and blocks metastasis pathways

This is peptide science doing what it does best: elegant design, direct action, and new angles on tough problems. Anyone following peptide research knows these kinds of multifunctional platforms are where the field is heading. Sourcing quality compounds? Check the vendor directory.

Peptides aren’t just tools—they’re the vanguard of smarter cancer strategies. Watch this space.

Back to News Read original on Acta Biomater

Antimicrobial-potentiated colorectal cancer therapy with synchronized tumoricidal immunity via a self-deliverable nanopeptide.

Related Reading

Eu(3+)-mediated dual-crosslinked collagen-mimetic peptide/sodium alginate hydrogel for 3D-printed skin wound dressings.

Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.

Klotho-derived peptide preserves erectile function by limiting fibrosis, oxidative stress, and apoptosis of penile smooth muscle cells in cavernous nerve injured-rats through suppression of the TGF-β1/TGF-β type II receptor signaling.